Analyst Consensus ?
ConsensusHold35 ratings
Bullish1440.0%
Neutral2057.1%
Bearish12.9%
Baxter International Inc. · BAX · FY2025 Q1 · Calendar Q2 2025
Baxter: Strong HST momentum, tariffs temper the outlook
The supplied analysis supports a constructive but qualified view: focused products, HST momentum, Novum IQ demand, and a raised guidance sentiment support the trajectory, while tariffs, the China IV-solutions exit, margin deceleration, and execution around the portfolio changes are counterweights.
Reported Before market openNYSEHealthcare
$12.59B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $0.48
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $2.59B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-1.6%
Event window
SPY move
+0.7%
Same window
Abnormal move
-2.3%
Stock minus SPY
Volume
1.3×
Versus trailing sessions
Subsequent drift
-0.6%
Up to 20 sessions
BAXSPY benchmark
Ask FN2 about BAX FY2025 Q1
Transcript, numbers and history already loaded
What drove BAX's -1.6% move after FY2025 Q1 earnings?What changed in BAX's guidance and outlook in FY2025 Q1?Give me the bull and bear case for BAX after FY2025 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, guidance sentiment moved from maintained to raised. The latest analysis emphasizes Q1 momentum in HST and MPT, quantifies expected tariff exposure, and identifies the China IV-solutions exit as a growth headwind.
Guidance delta
Management guidance sentiment was raised, while tariff exposure of $60–$70 million for 2025 and an approximately 50-basis-point sales-growth impact from exiting China IV solutions remain stated considerations.
Key takeaways
- The analysis identifies HST and MPT as the main sources of Q1 strength.
- Care and Connectivity Solutions grew 7% globally, with U.S. capital orders up 20% and backlog growth near 20%.
- Tariff mitigation is underway, but management still expects a $60–$70 million 2025 earnings impact.
- The China IV-solutions exit is expected to reduce 2025 sales growth by about 50 basis points.
- CEO succession remains active, with a search firm engaged.
Management priorities
- Continue the Novum IQ rollout and digital enhancements for Care and Connectivity Solutions.
- Advance launches in nutrition, advanced surgery, and IV solutions.
- Pursue tariff mitigation and supply-chain optimization while working toward debt reduction and potential tuck-in acquisitions.
Follow BAX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$23.97Current
$15Low
$49.09Average
$105High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 7, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Citigroup | Neutral | Neutral | Maintain | Oct 5, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jul 31, 2026 |
| TD Cowen | Hold | Hold | Maintain | Jul 31, 2026 |
| Stifel | Hold | Hold | Maintain | Jul 31, 2026 |
| UBS | Neutral | Neutral | Maintain | Jul 28, 2026 |
| Goldman Sachs | Neutral | Neutral | Maintain | Jul 15, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 6, 2026 |
| Barclays | Overweight | Overweight | Maintain | May 4, 2026 |
| Morgan Stanley | Underweight | Underweight | Maintain | Dec 2, 2025 |
| Argus Research | Hold | Buy | Downgrade | Oct 31, 2025 |
| JP Morgan | Neutral | Neutral | Maintain | Feb 21, 2025 |
| B of A Securities | Neutral | Neutral | Maintain | Mar 5, 2024 |
| Keybanc | Overweight | Overweight | Maintain | Jul 31, 2023 |
| Deutsche Bank | Hold | Hold | Maintain | Apr 28, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Feb 10, 2023 |
| Raymond James | Market Perform | Outperform | Downgrade | Jan 5, 2023 |
| Jefferies | Hold | Hold | Maintain | Oct 12, 2022 |
| Credit Suisse | Outperform | Outperform | Maintain | Feb 5, 2021 |
| Piper Sandler | Neutral | Overweight | Downgrade | Jan 29, 2021 |
| Oppenheimer | Outperform | Outperform | Maintain | Jun 24, 2020 |
| SVB Leerink | Outperform | Outperform | Maintain | May 1, 2020 |
| CFRA | Hold | Hold | Maintain | Feb 6, 2020 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Nov 8, 2018 |
| Argus | Buy | Hold | Upgrade | Nov 2, 2018 |
| Leerink Swann | Outperform | Outperform | Maintain | Nov 1, 2018 |
| BMO Capital | Outperform | Outperform | Maintain | Nov 1, 2018 |
| PiperJaffray | Overweight | Overweight | Maintain | Jul 27, 2018 |
| Bank of America | Buy | Buy | Maintain | May 22, 2018 |
| Stifel Nicolaus | Hold | Hold | Maintain | Apr 30, 2018 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Jun 30, 2017 |
| CL King | Buy | Neutral | Upgrade | Sep 4, 2013 |
| Mizuho | Neutral | Buy | Downgrade | Nov 27, 2012 |
| Dougherty & Co. | Neutral | Neutral | Maintain | Mar 5, 2012 |
| Dougherty | Neutral | Neutral | Maintain | Mar 5, 2012 |
| Standpoint Research | Hold | Buy | Downgrade | Feb 16, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $23.97. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Analyst unavailable | $20 | $24.36 | -16.6% | Oct 6, 2026 |
| Stifel Nicolaus | Analyst unavailable | $28 | $26.75 | +16.8% | Jul 31, 2026 |
| UBS | Analyst unavailable | $25 | $24.49 | +4.3% | Jul 28, 2026 |
| Stifel Nicolaus | Rick Wise | $24 | $23.34 | +0.1% | Jul 28, 2026 |
| Goldman Sachs | Analyst unavailable | $21 | $21.8 | -12.4% | Jul 15, 2026 |
| Evercore ISI | Vijay Kumar | $24 | $22.22 | +0.1% | Jul 6, 2026 |
| Barclays | Analyst unavailable | $27 | $17.21 | +12.6% | May 4, 2026 |
| Goldman Sachs | Analyst unavailable | $17 | $20.54 | -29.1% | Feb 17, 2026 |
| UBS | Danielle Antalffy | $19 | $19.79 | -20.7% | Feb 16, 2026 |
| Deutsche Bank | Analyst unavailable | $20 | $19.23 | -16.6% | Feb 13, 2026 |
| Barclays | Analyst unavailable | $25 | $18.71 | +4.3% | Feb 13, 2026 |
| Jefferies | Analyst unavailable | $19 | $18.71 | -20.7% | Feb 12, 2026 |
| Stifel Nicolaus | Analyst unavailable | $20 | $18.71 | -16.6% | Feb 12, 2026 |
| Barclays | Matt Miksic | $30 | $20.69 | +25.2% | Jan 9, 2026 |
| Goldman Sachs | Analyst unavailable | $23 | $20.69 | -4.0% | Jan 9, 2026 |
| Evercore ISI | Vijay Kumar | $23 | $20.02 | -4.0% | Jan 5, 2026 |
| Morgan Stanley | Patrick Wood | $15 | $19.08 | -37.4% | Dec 2, 2025 |
| Goldman Sachs | David Roman | $22 | $18.81 | -8.2% | Oct 31, 2025 |
| Stifel Nicolaus | Analyst unavailable | $22 | $19.18 | -8.2% | Oct 30, 2025 |
| Barclays | Analyst unavailable | $36 | $22.44 | +50.2% | Aug 4, 2025 |
| UBS | Analyst unavailable | $24 | $22.44 | +0.1% | Aug 4, 2025 |
| Evercore ISI | Vijay Kumar | $42 | $29.26 | +75.2% | Jan 2, 2025 |
| Bank of America Securities | Travis Steed | $45 | $36.32 | +87.7% | Oct 4, 2024 |
| Jefferies | Matthew Taylor | $42 | $36.92 | +75.2% | Aug 6, 2024 |
| Morgan Stanley | Patrick Wood | $30 | $35.32 | +25.2% | Jul 15, 2024 |
| Goldman Sachs | David Roman | $36 | $33.31 | +50.2% | Jun 12, 2024 |
| UBS | Danielle Antalffy | $40 | $36.91 | +66.9% | May 3, 2024 |
| Jefferies | Matthew Taylor | $43 | $36.89 | +79.4% | May 2, 2024 |
| Stifel Nicolaus | Rick Wise | $44 | $36.72 | +83.6% | May 2, 2024 |
| Barclays | Matt Miksic | $54 | $45.26 | +125.3% | Jul 31, 2023 |
| Jefferies | Philippe Houchois | $85 | $47.01 | +254.6% | Jul 31, 2023 |
| Citigroup | Joanne Wuensch | $44 | $39.71 | +83.6% | Mar 27, 2023 |
| Raymond James | Analyst unavailable | $85 | $70.35 | +254.6% | Apr 29, 2022 |
| Wells Fargo | Analyst unavailable | $90 | $70.2 | +275.5% | Apr 29, 2022 |
| Bank of America Securities | Travis Steed | $100 | $85.19 | +317.2% | Mar 3, 2022 |
| Morgan Stanley | David Lewis | $105 | $82.35 | +338.0% | Feb 18, 2022 |
| Goldman Sachs | Amit Hazan | $91 | $85.91 | +279.6% | Feb 13, 2022 |
| Citigroup | Joanne Wuensch | $101 | $87.16 | +321.4% | Jan 7, 2022 |
| J.P. Morgan | Robbie Marcus | $95 | $83.36 | +296.3% | Dec 17, 2021 |
| Cowen & Co. | Josh Jennings | $98 | $82.93 | +308.8% | Dec 13, 2021 |
| Piper Sandler | Matthew O'Brien | $82 | $80.49 | +242.1% | Sep 2, 2021 |
Track every rating change on BAX the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationBaxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units.…
Historical context
All BAX earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
Latest beats and misses
Who reports nextBeat on EPS
- LWFY2027 Q1 · October 6, 2026+27.8% EPS+7.5% move
- RPMFY2027 Q1 · October 6, 2026+1.5% EPS+3.2% move
- ACNFY2026 Q4 · October 1, 2026+3.5% EPS+15.8% move
- MKCFY2026 Q3 · October 1, 2026+13.9% EPS-4.9% move
- NKEFY2027 Q1 · October 1, 2026+10.0% EPS-0.7% move
- CAGFY2027 Q1 · September 30, 2026+44.4% EPS-4.9% move
Get the BAX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-04-17T00:02:52.217204+00:00
- Polygon adjusted daily market bars · 2026-10-07T18:30:42.111115+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-07T18:30:42.108266+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-07. For educational purposes only; not investment advice.